BR112023021383A2 - Composto da fórmula geral 1, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 2, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 3, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 4, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 5, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composição farmacêutica; e; uso do composto, ou do isômero, da forma cristalina, do sal farmaceuticamente aceitável, do hidrato ou do solvato do mesmo - Google Patents
Composto da fórmula geral 1, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 2, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 3, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 4, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 5, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composição farmacêutica; e; uso do composto, ou do isômero, da forma cristalina, do sal farmaceuticamente aceitável, do hidrato ou do solvato do mesmoInfo
- Publication number
- BR112023021383A2 BR112023021383A2 BR112023021383A BR112023021383A BR112023021383A2 BR 112023021383 A2 BR112023021383 A2 BR 112023021383A2 BR 112023021383 A BR112023021383 A BR 112023021383A BR 112023021383 A BR112023021383 A BR 112023021383A BR 112023021383 A2 BR112023021383 A2 BR 112023021383A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- solvate
- isomer
- hydrate
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 14
- 150000003839 salts Chemical class 0.000 title abstract 14
- 239000012453 solvate Substances 0.000 title abstract 12
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000012661 PARP inhibitor Substances 0.000 abstract 2
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110439238 | 2021-04-22 | ||
| PCT/CN2022/087652 WO2022222921A1 (zh) | 2021-04-22 | 2022-04-19 | 含哌嗪结构的parp抑制剂、其制备方法及医药用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023021383A2 true BR112023021383A2 (pt) | 2023-12-19 |
Family
ID=83721971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023021383A BR112023021383A2 (pt) | 2021-04-22 | 2022-04-19 | Composto da fórmula geral 1, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 2, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 3, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 4, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 5, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composição farmacêutica; e; uso do composto, ou do isômero, da forma cristalina, do sal farmaceuticamente aceitável, do hidrato ou do solvato do mesmo |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240336624A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4328224A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024514703A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230175225A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117279916B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022261011A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023021383A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3213029A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023012361A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022222921A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202309025A (zh) * | 2021-04-19 | 2023-03-01 | 美商辛瑟拉股份有限公司 | Parp1抑制劑及其用途 |
| CN116867783B (zh) * | 2021-04-23 | 2026-08-07 | 康百达(四川)生物医药科技有限公司 | 吡啶衍生物及其在医药上的应用 |
| WO2023046034A1 (zh) * | 2021-09-22 | 2023-03-30 | 明慧医药(杭州)有限公司 | 一种含氮杂环化合物、其制备方法、其中间体及其应用 |
| WO2023046149A1 (zh) * | 2021-09-26 | 2023-03-30 | 张文燕 | 喹喔啉类化合物及其医药用途 |
| WO2023046158A1 (zh) * | 2021-09-26 | 2023-03-30 | 张文燕 | 氮杂喹啉酮类化合物及其医药用途 |
| WO2023051812A1 (zh) * | 2021-09-30 | 2023-04-06 | 海思科医药集团股份有限公司 | 含氮杂环衍生物parp抑制剂及其用途 |
| TWI876212B (zh) | 2021-10-01 | 2025-03-11 | 美商辛瑟拉股份有限公司 | 吖丁啶及吡咯啶parp1抑制劑及其用途 |
| CN118434725B (zh) * | 2022-01-20 | 2026-01-02 | 微境生物医药科技(上海)有限公司 | 吡啶酰胺类parp抑制剂、及其制备方法和医药用途 |
| CN120081844A (zh) | 2022-01-21 | 2025-06-03 | 新特拉有限公司 | Parp1抑制剂及其用途 |
| US20250214980A1 (en) | 2022-03-14 | 2025-07-03 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| PT4497438T (pt) | 2022-04-28 | 2025-10-31 | Xinthera Inc C/O Gilead Sciences Inc | Inibidores tricíclicos da parp1 e suas utilizações |
| AU2023275808A1 (en) * | 2022-05-25 | 2024-12-12 | Xizang Haisco Pharmaceutical Co., Ltd. | Bicyclic derivative parp inhibitor and use thereof |
| US20250346573A1 (en) * | 2022-06-02 | 2025-11-13 | Chengdu Easton Biopharmaceuticals Co., Ltd. | Azaquinolinone derivative, preparation method therefor and use thereof |
| CN115919859B (zh) * | 2022-07-14 | 2024-01-05 | 四川海思科制药有限公司 | 一种杂芳基衍生物的药物组合物及其在医药上的应用 |
| CN119677736A (zh) * | 2022-08-24 | 2025-03-21 | 四川海思科制药有限公司 | 一种杂芳基衍生物parp抑制剂药学上可接受的盐及其用途 |
| WO2024041608A1 (zh) * | 2022-08-24 | 2024-02-29 | 四川海思科制药有限公司 | 一种杂芳基衍生物parp抑制剂的晶体形式及其用途 |
| CN117658983A (zh) * | 2022-09-01 | 2024-03-08 | 浙江文达医药科技有限公司 | 选择性parp1抑制剂 |
| CN117946074A (zh) * | 2022-10-20 | 2024-04-30 | 上海海和药物研究开发股份有限公司 | 具有parp1抑制活性的化合物及其用途 |
| CN120092010A (zh) * | 2022-11-02 | 2025-06-03 | 轩竹生物科技股份有限公司 | 多环类聚(adp核糖)聚合酶选择性抑制剂 |
| AU2023412594A1 (en) * | 2022-12-23 | 2025-07-10 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | Parp1 inhibitors |
| WO2024213111A1 (zh) * | 2023-04-14 | 2024-10-17 | 微境生物医药科技(上海)有限公司 | Parp抑制剂、其制备方法及医药用途 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009053373A1 (en) * | 2007-10-26 | 2009-04-30 | Janssen Pharmaceutica Nv | Quinolinone derivatives as parp inhibitors |
| EP2389379A1 (en) * | 2009-01-23 | 2011-11-30 | Takeda Pharmaceutical Company Limited | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors |
| EP2415767B1 (en) * | 2009-03-27 | 2014-09-03 | Takeda Pharmaceutical Company Limited | Poly (ADP-ribose) Polymerase (PARP) Inhibitors |
| PT3312177T (pt) * | 2015-06-09 | 2021-05-17 | Onconic Therapeutics Inc | Composto derivado tricíclico, método para preparar o mesmo e composição farmacêutica compreendendo o mesmo |
| PT3562822T (pt) * | 2016-12-30 | 2021-06-02 | Mitobridge Inc | Inibidores de poli-adp ribose polimerase (parp) |
| TWI837403B (zh) * | 2019-07-19 | 2024-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| TW202309025A (zh) * | 2021-04-19 | 2023-03-01 | 美商辛瑟拉股份有限公司 | Parp1抑制劑及其用途 |
| CN117177972A (zh) * | 2021-04-19 | 2023-12-05 | 新特拉有限公司 | Parp1抑制剂及其用途 |
| CN116710433B (zh) * | 2021-04-23 | 2026-05-05 | 康百达(四川)生物医药科技有限公司 | 一种选择性parp1抑制剂及其应用 |
| TW202304911A (zh) * | 2021-04-23 | 2023-02-01 | 大陸商南京明德新藥研發有限公司 | 吡啶醯胺類化合物 |
-
2022
- 2022-04-19 WO PCT/CN2022/087652 patent/WO2022222921A1/zh not_active Ceased
- 2022-04-19 CA CA3213029A patent/CA3213029A1/en active Pending
- 2022-04-19 JP JP2023564639A patent/JP2024514703A/ja active Pending
- 2022-04-19 US US18/281,855 patent/US20240336624A1/en active Pending
- 2022-04-19 KR KR1020237038365A patent/KR20230175225A/ko active Pending
- 2022-04-19 MX MX2023012361A patent/MX2023012361A/es unknown
- 2022-04-19 CN CN202280029738.3A patent/CN117279916B/zh active Active
- 2022-04-19 AU AU2022261011A patent/AU2022261011A1/en active Pending
- 2022-04-19 BR BR112023021383A patent/BR112023021383A2/pt unknown
- 2022-04-19 EP EP22791028.8A patent/EP4328224A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240336624A1 (en) | 2024-10-10 |
| EP4328224A4 (en) | 2025-06-18 |
| EP4328224A1 (en) | 2024-02-28 |
| CN117279916A (zh) | 2023-12-22 |
| CN117279916B (zh) | 2026-04-21 |
| MX2023012361A (es) | 2023-10-31 |
| AU2022261011A1 (en) | 2023-11-16 |
| KR20230175225A (ko) | 2023-12-29 |
| JP2024514703A (ja) | 2024-04-02 |
| WO2022222921A1 (zh) | 2022-10-27 |
| CA3213029A1 (en) | 2022-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY39029A (es) | Uso de compuestos de aminopropionato sustituido en el tratamiento de la infección por sars-cov-2 | |
| BR112022020962A2 (pt) | Derivados de imidazolidinona e uso médico dos mesmos | |
| MX2024011317A (es) | Procesos para la preparación de derivados sustituidos de espirooxindol. | |
| BRPI0720220B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo | |
| MX2023012361A (es) | Inhibidor de parp que contiene estructura de piperazina, metodo de preparacion del mismo y uso farmaceutico del mismo. | |
| BR112023003832A2 (pt) | Compostos inovadores como inibidor de histona desacetilase 6 e composição farmacêutica que compreende os mesmos | |
| CL2022003646A1 (es) | Derivados de amidopirimidona | |
| EA202092168A1 (ru) | Применение фавипиравира в лечении коронавирусной инфекции | |
| BR112022009209A2 (pt) | Derivado de amida e método de preparação e uso do mesmo na medicina | |
| BR112022009705A2 (pt) | Forma cristalina anidra de um derivado de ácido 7h-benzo[7]anuleno-2-carboxílico, seus usos e processos de preparação, forma sólida, medicamento e composição farmacêutica | |
| UY29825A1 (es) | Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones | |
| PH12020552244A1 (en) | Heterocyclic compounds as trk inhibitors | |
| CL2023002578A1 (es) | Derivados de alfa-d-galatopiranosido triazolil-metil sustituidos | |
| BRPI0719920B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo e composto intermediário | |
| BR112022003562A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de fibrose de órgãos | |
| BR112023025841A2 (pt) | Forma cristalina de tolebrutinibe, método de preparação para mesma e uso da mesma | |
| BR112012011310A2 (pt) | compostos derivados de 8-azabiciclo[3.2.1]octano-8-carboxamida, seu medicamento, seu agente terapêutico e seu uso | |
| BR112023002077A2 (pt) | Composto e seu uso, composição e formulação farmacêutica | |
| BR112022021748A2 (pt) | Compostos e composições para inibir a atividade de hif2a e seus métodos de uso | |
| CO2018001700A2 (es) | Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos | |
| BR112018010107A2 (pt) | composição farmacêutica para o tratamento ou prevenção de nash | |
| CL2023002322A1 (es) | Derivados de hidroxiheterocicloalquil-carbamoilo | |
| BR112022004099A2 (pt) | Composto, composição farmacêutica, uso do composto, e, método para o tratamento de uma doença relacionada ao atx | |
| MX389786B (es) | Derivados de 4-metil 7-{[5-heterociclilpirazina-2-il]amino}1,2- dihidro-1,6-naftiridina-5-ona como compuestos inhibidores de cdk4/6 y el uso de los mismos para el tratamiento de cáncer. | |
| DOP2025000046A (es) | Inhibidores de topoisomerasa-1 derivados de exatecán composiciones farmacéuticas y sus usos |